Figure 3
Ixazomib induces apoptosis in ESCC. Kyse150 and Kyse510 cells were treated with ixazomib for 48 h. (A, B) Apoptosis was determined by FACS analysis using Annexin V-FITC/PI double-staining kit and Annexin V+ cell populations were defined as apoptosis. (C),Treatment with ixazomib increased the expression of caspase3 and decrease the expression of Bcl-2. ESCC cells were treated with ixazomib for 48 h and cell lysates were assessed by western blot. GAPDH was used as loading control. Values are the means ± SEM (n = 5-6). *P < 0.05 or **P < 0.01 indicates significant differences from the vehicle group as assessed by a two-tailed unpaired Student’s t test.